Merck has announced that its anti-PD-1 therapy, Keytruda (pembrolizumab), in combination with chemotherapy and radiotherapy, has demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy and radiotherapy alone in patients with newly diagnosed high-risk locally advanced cervical cancer. The phase 3 KEYNOTE-A18 trial met one of its primary endpoints of PFS. A favorable trend in overall survival (OS) was also observed, but the data were not mature at the interim analysis. The safety profile of Keytruda was consistent with previous studies, and no new safety signals were identified. Detailed results will be presented at an upcoming medical meeting and will be submitted to regulatory authorities. Keytruda is currently approved for certain patients with persistent, recurrent, or metastatic cervical cancer in the US.
Wed, 19 Jul 2023 10:45:00 GMT | Merck